iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
- None.
- None.
The partnership between iBio and AstralBio signifies an innovative approach to addressing obesity and cardiometabolic conditions, leveraging iBio's AI/Machine Learning platform and AstralBio's drug development expertise. The focus on developing novel antibodies, particularly those targeting the TGFb superfamily, suggests a strategic move towards highly specialized treatments in a market that is increasingly demanding precision medicine. This collaboration could enhance the competitive edge for both companies, potentially leading to breakthrough therapies that may improve treatment efficacy and patient tolerability.
The $15M PIPE financing is a strong financial move, ensuring the companies have the necessary resources to sustain research and development efforts. The financial stability provided by this investment could lead to increased investor confidence, potentially impacting iBio's stock valuation positively in the long term, especially if the collaboration yields successful IND applications and subsequent drug development milestones.
From an investment perspective, the collaboration between iBio and AstralBio represents a strategic allocation of capital towards a high-potential segment of the biotech industry. The use of AI in drug discovery and development is a cutting-edge trend that has the potential to disrupt traditional R&D processes, reducing both time and cost. The exclusive license agreement for AI-powered technology and the option rights for cardiometabolic targets could be a significant value driver for iBio, as it diversifies its portfolio and taps into the lucrative obesity treatment market.
Furthermore, the timing of the announcement, closely following the PIPE financing, is indicative of a well-planned capital deployment strategy. Investors should monitor the progress of the lead program, as successful pre-clinical results could act as a catalyst for iBio's stock performance. However, it is also important to consider the inherent risks of drug development, as any setbacks could negatively affect investor sentiment and stock value.
The collaboration's scientific underpinnings are noteworthy, with the targeting of the TGFb superfamily offering a novel approach to muscle wasting and obesity treatments. The AI-driven epitope steering, combined with the StableHu antibody optimizer and mammalian display, indicates a sophisticated method of antibody development that could result in highly specific and effective therapeutics. The potential expansion of the collaboration to include additional targets underscores the dynamic nature of this partnership and its capacity to innovate within the biologics space.
It is essential to track the development milestones and the IND application process, as these will provide tangible evidence of the collaboration's success and the viability of the AI/Machine Learning platform in drug discovery. The partnership's ability to produce a best-in-class profile for the lead program could have profound implications not only for patient outcomes but also for the broader industry's approach to treating complex diseases like obesity and cardiometabolic disorders.
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –
– iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets –
– Concurrent
– Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration –
BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.
Yesterday, iBio announced the closing of a
The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise. As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four (4) targets for the treatment of cardiometabolic disease, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug (IND) application. iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise. As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a novel lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity. Upon mutual consent, the parties may also expand the collaboration to include additional targets in other fields.
“We are confident our AI-enabled technology is exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic space,” said iBio’s Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D. “The future of treating millions of patients affected by obesity and cardiometabolic disease globally will rely on next generation therapies aimed at enhancing both the efficacy and the tolerability profiles of current treatments. Notably, the collaboration’s lead program targeting the TGFb superfamily is designed to achieve a best-in-class profile. Our approach, which combines AI-driven epitope steering with the StableHu antibody optimizer and mammalian display, aims to validate proof of concept studies that underscore the immense potential of anti-myostatin strategies. Over the coming months, we expect to announce additional novel targets, each promising a similarly transformative profile.”
Dr. Brenner added, “Leveraging my experience in obesity and cardiometabolic disease drug development from my time at Eli Lilly and Pfizer, I am eager to advance potentially groundbreaking compounds through our partnership with AstralBio, a team renowned for its entrepreneurship and track record to develop best-in-class and first-in-class therapies.”
“We are excited to collaborate with the talented iBio team to rapidly advance exciting targets in cardiometabolic disease and beyond. Using machine learning tools in the discovery of biological drugs has the potential to shorten development timeframes and lower expenses while enhancing the likelihood of successful development. We look forward to working with iBio to mutually advance our goals to deliver meaningful precision therapies for patients efficiently,” said Patrick Crutcher, AstralBio’s Co-founder and Chief Executive Officer.
About iBio
iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for obesity, cardiometabolic, hard-to-target cancers, and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
About AstralBio
AstralBio is a privately held biotechnology company founded by Patrick Crutcher and several former team members of ValenzaBio and AlmataBio. AstralBio's mission is to develop first-in-class or best-in-class medicines to treat cardiometabolic and immune-mediated diseases. The company plans to leverage iBio’s proven machine learning-enabled platform to accelerate the progression of novel therapeutic targets to transform patient care.
Webcasted Conference Call Details
iBio will host a webcasted conference call with an associated slide presentation today, March 27, at 8:30 a.m. EDT to discuss its collaboration with AstralBio.
The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. To participate in the conference call by telephone, please pre-register via this link to receive the dial-in number and your unique PIN.
Forward-Looking Statements
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the intended use of proceeds, the expected gross proceeds from the offering and the expected extension of the Company’s cash runway to fund its operating plan into 2025, the ability to build a diverse set of novel best-in-class obesity treatments, the Company’s AI-enabled technology being exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic disease space, the collaboration’s lead program targeting the TGFb superfamily achieving a best-in-class profile, the size of the obesity market, aiming to pioneer antibody treatments for obesity and cardiometabolic diseases and advancing potentially groundbreaking compounds through the Company’s partnership with AstralBio. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all, the ability to develop antibodies against challenging targets in the cardiometabolic disease space, the ability to finance when needed and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contacts:
Investor Relations
Stephen Kilmer
iBio, Inc.
(646) 274-3580
skilmer@ibioinc.com
Media Relations
Susan Thomas
iBio, Inc.
(619) 540-9195
susan.thomas@ibioinc.com
